drugset / Trial / NCT01605513
Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether PEG-IFN-SA is safe, tolerant and effective in the treatment of HCV patients.
Timeline
- Start
- 2011-06
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEG-IFN-SA | Protein / enzyme biologic | 1 ug/kg | Subcutaneous |
| Subject | PEG-IFN-SA | Protein / enzyme biologic | 1.5 ug/kg | Subcutaneous |
| Subject | PEG-IFN-SA | Protein / enzyme biologic | 2 ug/kg | Subcutaneous |
| Subject | PEG-IFN-SA | Protein / enzyme biologic | 3 ug/kg | Subcutaneous |